Incyte’s ruxolitinib cream formulations look strong in Phase 3 atopic dermatitis
pharmafile | April 7, 2020 | News story | Manufacturing and Production, Research and Development | Incyte, atopic dermatitis, ruxolitinib
Incyte has lifted the curtain on promising new Phase 3 data for its 0.75% and 1.5% twice daily cream formulations of ruxolitinib in the treatment of mild-to-moderate atopic dermatitis.
The findings from two studies were presented at the Revolutionizing Atopic Dermatitis Virtual Symposium on Sunday; both met their main goal, with a greater proportion of ruxolitinib patients achieving an Investigator’s Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at least a two-point improvement from baseline after eight weeks of treatment.
In the first study, the data showed that 40.4% and 52.2% of patients receiving ruxolitinib 0.75% and 1.5% respectively achieved at least a score of 4 on the Itch Numerical Rating Scale at eight weeks, representing a clinically meaningful reduction in itch. In the second study, this was recorded as 42.7% and 50.7% of patients respectively by the same point.
Furthermore, ruxolitinib users saw a “significantly greater” reduction on the Scale within 12 hours of treatment compared to non-medicated cream.
Dr Jim Lee, Incyte’s Group Vice President, Inflammation & AutoImmunity, said that the cream “significantly reduced both the skin inflammation and itch associated with atopic dermatitis. The reduction in itch can potentially improve key disease-related and quality of life outcomes for patients living with atopic dermatitis.”
He added: “We are pleased to share these important data with the dermatology community, as they support the potential of ruxolitinib cream to become an important antipruritic and anti-inflammatory treatment option for patients with atopic dermatitis, and we look forward to submitting a New Drug Application (NDA) to the U.S. Food and Drug Administration later this year.”
Matt Fellows
Related Content
UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …
Dupixent improves symptoms in patients with skin of colour, study shows
Sanofi and Regeneron have announced results from the collaborative phase 4 DISCOVER study, presented at …
Sanofi shares phase 2b results for dermatitis treatment
Sanofi has shared positive results from part 2 of the investigational phase 2b STREAM-AD study …
